Regenerative medicine company Orthocell Limited (ASX:OCC) has appointed Samson Medical Technologies (SMT) as its exclusive distributor of Striate+ (CelGro Dental) for bone and soft tissue repair across the Australia.
Orthocell Managing Director, Paul Anderson, said SMT is a leading distributor of innovative medical devices with an experienced team to assist in managing the market entry, promotion and distribution of Striate+TM.
“SMT is the ideal partner in our local market with established relationships with oral surgeons and a successful track record driving market entry of high-quality products.”
The distributor agreement follows inclusion of Striate+ on the Australian Prostheses List. Inclusion on the prostheses List enables dental practitioners to receive reimbursement from private insurers for use of Striate+ in approved dental bone and soft tissue repair procedures, reducing costs to the patient.
SMT will distribute Striate+ for use in bone and soft tissue repair across Australia undertaking targeted promotion activities, initiating sales, as well as expanding the network of referring periodontists and oral and maxillofacial surgeons.
The exclusive distribution agreement has a term of five years and enables Orthocell access to this strategic market, with a growing uptake of Australian made high quality products.
Founder and CEO at Samson Medical Technologies, Andrew Nutman, said that Samson Medical Technologies believe in investing in technologies that will not only grow its business but will also add value to our customers and benefit the patients they treat on a daily basis.
“We look forward to working with the team at Orthocell to make Striate+ (CelGro Dental) the product of choice amongst the oral surgical and dental implant industry.”
Mr Anderson said that with a panel of experts and now a distributor in place, Orthocell is well positioned to gain market traction in Australia, as it works to expand into the US, the largest healthcare market and establish Striate+ as the highest quality collagen membrane for oral bone and soft tissue regeneration procedures.
Striate+ is a premium dental membrane with market uptake driven by the surgeon’s preference for high quality, easy to use devices facilitating better patient outcomes. Clinical studies have shown using Striate+ supported transition from two-stage to single-stage dental procedures, reducing the procedure time by several months. This is of significant interest to patients and clinicians due to potential improvements in efficiency and efficacy of dental procedures.
